On Tuesday, Shares of Citigroup Inc. (NYSE:C), gained 0.63% to $56.
Citigroup, declared the commencement of offers to purchase for cash certain of its notes of the series set forth in the table below up to an aggregate principal amount with respect to each series of notes. The offer to purchase each series of Notes is referred to as an “Offer” and all such offers are referred to collectively as the “Offers.” The Notes had an aggregate principal amount outstanding of about U.S. $2.35 billion as of June 8, 2015.
These Offers, presently totaling up to about U.S. $500 million aggregate principal amount of the Notes, are consistent with Citigroup’s liability administration strategy, and reflect its ongoing efforts to enhance the efficiency of its funding and capital structure. Since 2013, Citigroup redeemed or stepped down U.S. $26.8 billion of securities, not taking into account exchanged securities, of which U.S. $4.7 billion was redeemed or stepped down in 2015, reducing Citigroup’s overall funding costs. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, counting without limitation, the economic value, potential impact on Citigroup’s net interest margin and borrowing costs, the overall remaining tenor of Citigroup’s debt portfolio, capital impact, in addition to overall market conditions.
Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. The company operates through two segments, Global Consumer Banking (GCB) and Institutional Clients Group (ICG).
Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII), inclined 6.52% to $0.49, during its last trading session.
During Tuesday’s trade, 7,035,879 shares exchanged hands as compared to its average daily volume of 1,733,250. The company holds the market capitalization of $28.04M.
RXi Pharmaceuticals, declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
Importantly, this patent expands the scope of RXi’s self-delivering RNAi platform with the incorporation of novel oligonucleotide chemical modifications. These chemical modifications result in improved biodistribution following systemic administration and may be beneficial for local delivery applications in the central nervous system.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
Finally, Time Warner Inc. (NYSE:TWX), ended its last trade with -0.57% loss, and closed at $85.53.
Time Warner, declared the expiration of its tender offer (the “Offer”) to purchase for cash any and all of the outstanding 5.875% Notes due 2016 (CUSIP No. 887317AC9) of Time Warner Inc. (the “Notes”). The Offer expired at 5:00 p.m., New York City time, on June 3, 2015 (the “Expiration Time”).
As of the Expiration Time, $687,092,000 aggregate principal amount of outstanding Notes had been validly tendered and accepted. This amount comprises $610,000 aggregate principal amount of outstanding Notes tendered following the guaranteed delivery procedures described in the Offer to Purchase regarding the Offer, which remain subject to the Note holders’ performance of the delivery requirements under such procedures.
Time Warner Inc. operates as a media and entertainment company in the United States and internationally. It operates through three segments: Turner, Home Box Office, and Warner Bros.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.